Active Ingredient History
Veltuzumab is a monoclonal antibody which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Rheumatoid (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 1/Phase 2)
Squamous Intraepithelial Lesions (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue